Mouse studies suggest mAbs
against DLL1 and DLL4 could be useful for preventing GvHD. In a mouse model
for GvHD, transient treatment with mAbs against Dll1 and Dll4 decreased
disease severity and increased survival compared with control mAbs. Next
steps include characterizing the long-term effects of the anti-DLL1/DLL4
mAbs.
The Genentech Inc. unit of Roche collaborated on the
study but has not disclosed whether it has an anti-DLL1/DLL4 mAb in
preclinical development.
At least four companies have compounds targeting DLL4 in Phase I testing or
earlier to treat various cancers.

Access this BioCentury Innovations article Distillery article for your individual use via a permanent link that allows you to read or print the article: $18.
The article link will be posted on the purchase transaction web page, and also emailed to you with your purchase confirmation.

Purchase This Article for Limited One-Time Distribution and Posting to Your Website :

Receive a formatted PDF reprint of this article with rights for limited one-time redistribution and posting to your website: $750. Please allow 24-48 hours for delivery.

Purchase Options

Purchase this article for individual use $18 USDPurchase this article for limited one-time distribution and website posting $750 USD